On September 14, 2026 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, reported the issuance of a EUR 500 million bond with a coupon of 4.835% and a maturity of 12 years, for general corporate purposes including the refinancing of existing debt.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sandoz CFO Remco Steenbergen says: "The successful issuance of this 12-year EUR 500 million bond underlines the strength of our financial foundation at Sandoz and extends the maturity profile of our debt portfolio. Our proactive interest rate risk management substantially mitigated the impact of recent increases in market interest rates and enabled us to secure it at an attractive effective interest cost, below the bond’s contractual coupon. Through continued discipline in debt management, we have achieved a diversified, well-balanced maturity profile and meaningful reductions in funding costs."

Including this transaction, Sandoz expects to maintain an average annual interest rate on gross debt below 4%, further reinforcing its resilient capital structure through a debt maturity profile extending to 2038 and an average debt maturity of approximately six years, excluding bonds maturing through 2027.

Sandoz aims to maintain an investment grade credit rating and is rated Baa2 (positive outlook) by Moody’s and BBB (positive outlook) by S&P.

The transaction was supported by a bank syndicate consisting of Bank of America, Mizuho and SEB as active bookrunners and Citi, HSBC and Société Générale as passive bookrunners. Advestra and Linklaters acted as Sandoz legal advisors.

(Press release, Sandoz, SEP 14, 2026, View Source [SID1234670832])

On September 14, 2026 OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, reported details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations from OmniAb’s executive leadership team, including corporate updates, select partner programs, the xPloration platform, technology innovations and a Q&A session. For those attending in person, there will be demonstrations of the Company’s xPloration technology platform and laboratory tours.

OmniAb Investor & Analyst Day
Date: October 6, 2026
Time: 8 a.m. PT / 11 a.m. ET
Location: OmniAb Corporate Headquarters, Emeryville, CA
Participation: In person and virtually

(Press release, OmniAb, SEP 14, 2026, View Source;Analyst-Day-on-October-6-2026/default.aspx [SID1234670831])

On September 14, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA’s Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The "Study May Proceed" notice from the FDA allows the Company to examine TBS-2025 in a Phase 1b study evaluating the safety and potential efficacy of monotherapy at different doses in patients with relapsed/refractory (r/r) mutNPM1 AML who have failed to respond to or relapsed after menin inhibitor therapy. Following review of the safety data with the FDA, the study is expected to progress to the dose-optimization stage of the trial to determine a safe and biologically effective dose. Patients with r/r mutNPM1 AML who fail menin inhibitor therapy have no approved or effective treatments and represent an unmet medical need. If TBS-2025 results in encouraging response rates during the dose optimization stage of the study, the Company will explore with the FDA the potential expansion of the trial in consideration for the opportunity for accelerated approval.

"As the only known company to advance a VISTA-inhibiting mAb through the FDA’s IND process into a Phase 1b study in mutNPM1 AML, this is a major milestone for the Company and a testament to our commitment to advancing novel therapies to address the unmet needs of patients with AML," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "Research has shown that patients whose leukemic cells express VISTA have a poor response to therapy and significantly shorter survival. Studies have demonstrated that TBS-2025’s ability to block VISTA on leukemic cells has resulted in dramatic improvement in survival in studies of murine models of human AML, and we hope to translate this promising underlying science into a potentially safe and effective new treatment for patients with AML. We are excited for this next phase of our growth and by what it could mean for patients with AML."

About TBS-2025
TBS-2025 is a unique VISTA-inhibiting monoclonal antibody. VISTA is a novel checkpoint expressed on quiescent (resting) T cells and highly expressed on myeloid cells, notably myeloid-derived suppressor cells (MDSCs). Scientific evidence demonstrates that mutNPM1 drives the expression of VISTA on leukemic blasts, which is reported to be the primary mechanism by which AML escapes recognition by the patient’s immune system, resulting in low response rates of short duration following current therapies, including recently approved menin inhibitors. When VSIR, the gene that encodes for VISTA, is edited not to produce VISTA in murine models of mutNPM1 AML, an immune response is observed and survival is enhanced. Similarly, in a murine model of AML, TBS-2025 resulted in an increase in survival comparable to the intensive chemotherapy regimen that is currently used in front line treatment of patients with AML. When combined with intensive chemotherapy, survival was markedly improved. Collectively, these translational data underscore the potential for TBS-2025 in the treatment of patients with AML.

(Press release, TuHURA Biosciences, SEP 14, 2026, View Source [SID1234670830])

On September 14, 2026 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, reported that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed through the Investors section of the Company’s website at www.lyell.com. A replay of the webcast will be available on the Company’s website following the event.

(Press release, Lyell Immunopharma, SEP 14, 2026, View Source [SID1234670829])

On September 14, 2026 Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, reported that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux’s novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation. Over time, Janux intends to evaluate JANX013 in combination with additional candidates within its prostate cancer portfolio.

Prostate cancer is the most commonly diagnosed cancer in men, excluding skin cancers. Clinical experience with Janux’s PSMA-targeted T cell engager candidates has demonstrated the potential of tumor-activated T cell immunotherapy in patients with metastatic castration-resistant prostate cancer. CD28 is a key co-stimulatory receptor involved in T-cell activation, expansion, and persistence. JANX013 is designed to selectively deliver CD28 co-stimulation within the tumor microenvironment using Janux’s proprietary tumor-activation technology, with the goal of further enhancing the durability of anti-tumor immune responses while minimizing systemic CD28 activation.

"Co-stimulation plays a critical role in promoting sustained T-cell function and persistence," said Simon Butikofer, M.D., Vice President, Clinical Development. "JANX013 is designed to selectively deliver tumor-restricted co-stimulation in combination with our CD3 T cell engagers, with the goal of extending the durability of anti-tumor immune responses."

"The initiation of the JANX013 clinical program represents an important milestone in the continued evolution of our prostate cancer franchise," said David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics. "By combining complementary tumor-activated immunotherapies, we believe we have an opportunity to further improve long-term outcomes for patients with prostate cancer."

The Phase 1 clinical trial (NCT07813637) is a first-in-human, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013 in combination with JANX007 in adult patients with mCRPC. In addition to evaluating safety, the study is intended to evaluate biomarkers of immune activation, including T-cell expansion and persistence, to characterize the effects of tumor-restricted CD28 co-stimulation and inform future clinical development of JANX013.

For additional information about the study, please visit ClinicalTrials.gov using the identifier NCT07813637.

(Press release, Janux Therapeutics, SEP 14, 2026, View Source [SID1234670828])